Table 2

Overview of ICS use in the study population

TotalLow ICSModerate ICSHigh ICS
No of subjects, n (%)13 180 (69.9)4361 (23.1)4457 (23.6)4362 (23.1)
Accumulated daily budesonide equivalent dose (µg), median (IQR)
 Total ICS579 (263–1041)164 (105–263)579 (473–658)1397 (1052–1894)
 Budesonide421 (164–658)158 (105–263)526 (421–631)947 (631–1262)
 Fluticasone proprionate904 (329–1644)164 (164–329)493 (329–658)1479 (986–1973)
 Fluticasone furoate454 (227–832)189 (76–302)454 (227–548)907 (454–1097)
 Beclometasone219 (110–460)110 (110–197)329 (197–526)395 (197–778)
 Mometasone658 (247–1085)132 (66–263)461 (157–707)888 (625–1430)
 Ciclesonide263 (132–395)132 (132–263)263 (197–395)461 (263–756)
No of individual users, n (%)
 Budesonide9410 (49.9)3550 (81.4)3682 (82.6)2178 (49.9)
 Fluticasone proprionate4901 (26.0)862 (19.8)1121 (25.2)2918 (66.9)
 Fluticasone furoate118 (0.6)18 (0.4)48 (1.1)52 (1.2)
 Beclometasone190 (1.0)58 (1.3)77 (1.7)55 (1.3)
 Mometasone51 (0.3)9 (0.2)10 (0.2)32 (0.7)
 Ciclesonide42 (0.2)15 (0.3)13 (0.3)14 (0.3)
  • Please note that individuals may have received more than one type of ICS.

  • ICS, inhaled corticosteroids.